Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation

Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation

<b>Background/Objectives</b>: Metabolic dysfunction-associated steatohepatitis (MASH) has become the leading cause of hepatocellular carcinoma and liver disorders globally. Nevertheless, only one expensive drug, resmetirom (Res), has been approved by the FDA for MASH treatment to date. H...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenxiu Liu, Fan Yao, Jinghan Wang, Nan Shao, Xinxin Cao, Zhengqi Dong, Bin Zhang, Xiaobo Sun
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Biomedicines
Subjects:
metabolic dysfunction-associated steatohepatitis (MASH)
combination therapy
metformin
resmetirom
lipidomic analysis
transcriptomic analysis
Online Access:https://www.mdpi.com/2227-9059/13/6/1315
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items